Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03612791 |
| Title | Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab (ATEZOLACC) |
| Acronym | ATEZOLACC |
| Recruitment | Active, not recruiting |
| Gender | female |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Gustave Roussy, Cancer Campus, Grand Paris |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | FRA |